Home > Urology > EAU 2019 > Bladder Cancer > Largest Safety Study of Its Kind with Atezolizumab in Metastatic Bladder Cancer

Largest Safety Study of Its Kind with Atezolizumab in Metastatic Bladder Cancer

Presented By
Prof. Axel Merseburger, Prof. Jens Bedke
Conference
EAU 2019
Trial
Phase 3, SAUL, IMvigor211

In the Breaking News session, Prof. Axel Merseburger (University Hospital Schleswig-Holstein, Germany) announced the first results from SAUL, a phase 3b study evaluating the safety of atezolizumab in 997 patients with locally advanced or metastatic urothelial carcinoma (mUC) including several clinically relevant populations reflective of real-world clinical practice. Data from the study showed that both safety and efficacy, a secondary endpoint, were consistent with previous studies in both the overall population and a subgroup of patients corresponding to the patient population of the pivotal phase 3 study IMvigor211 (“IMvigor211-like”) [1].

SAUL is the largest prospective safety study of a cancer immunotherapy in mUC and provides information about atezolizumab in a real-world setting. This open label, single-arm, multicentre study was designed to assess the safety of atezolizumab as a second- to fourth-line treatment for people with locally advanced or m...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on